ChromaDex, Inc.
11
3
4
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
9.1%
1 terminated/withdrawn out of 11 trials
83.3%
-3.2% vs industry average
0%
0 trials in Phase 3/4
20%
1 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants
Role: collaborator
Randomized, Open-label, Safety Study of Subcutaneous and Intramuscular Injections of Niagen® Plus
Role: lead
Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+
Role: collaborator
Nicotinamide Riboside Impact on Extracellular Nicotinamide Adenine Dinucleotide (NAD+)
Role: collaborator
Nicotinamide Riboside in Hospitalized Patients
Role: collaborator
NR in Chemo-induced Peripheral Neuropathy
Role: collaborator
Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients
Role: collaborator
A Study by ChromaDex to Assess the Effects of TRU NIAGEN on Cognitive Function, Mood and Sleep in Older Adults
Role: lead
A Study Investigating the Effects of Niagen™ in Healthy Adults.
Role: collaborator
Safety & Efficacy of Nicotinamide Riboside Supplementation for Improving Physiological Function in Middle-Aged and Older Adults
Role: collaborator
A Study of the Pharmacokinetics of Three Dosages of Niagen in Healthy Subjects
Role: collaborator
All 11 trials loaded